Growth of Health System-Based Specialty Pharmacy to Continue in 2020, Reducing Cost of Care
Although the prevalence of health system-based specialty pharmacies has grown steadily over the past decade, 2020 will mark a critical year.
Health Experts Concerned Coronavirus Could Lead to Drug Shortages
The number of US cases is low, but experts are raising concerns that reliance on China for pharmaceutical ingredients could result in drug shortages.
Operation Broadsword, was the agency’s first bilateral enforcement operation with the Government of India.
Per capita health spending for 160 million Americans in employer-sponsored health plans grew by 4.4% in 2018, marking the third consecutive year of growth above 4%.
In the current chaotic environment of reimbursement that depends on quality and cost savings, pharmacists should increase their presence.
A thorough review of the ancillary treatment options for chemotherapy-induced nausea and vomiting.
Over 90% of hospice and palliative care patients are prescribed opioid medications for pain management, and many individuals receive home care.
Suzanne Soliman, PharmD, founder of the Pharmacist Moms Group, said she believes that every situation is different when it comes to choosing the best remedy for children.
Simplici-T1 is the first study to test activation of glucokinase in patients with type 1 diabetes by evaluating daily oral TTP399 as an adjunct to insulin therapy.
In a recent study, researchers hypothesize providers’ safety concerns about treatment as a potential barrier.
States are increasingly adopting this law, and pharmacists should educate and prepare themselves to keep patients informed.
Diclofenac sodium topical gel was first approved by the FDA in 2007 as a prescription drug, and was indicated for the relief of osteoarthritis pain in joints responsive to topical treatment, particularly the joints of the hands, knees, and feet.
Phase 3 Trial Shows Pembrolizumab, Chemotherapy Improve Survival in Metastatic Triple-Negative Breast Cancer
In the pivotal phase 3 KEYNOTE-355 study, pembrolizumab (Keytruda, Merck) combined with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed programmed death-ligand 1 (PD-L1).
Top news from across the health care landscape.